Summit Therapeutics Inc. Other Nonoperating Income (Expense)
Summit Therapeutics Inc. (SMMT) reported Other Nonoperating Income (Expense) of $500.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-07-23
- Summit Therapeutics Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was $500.00K.
- Summit Therapeutics Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was $0.00.
- Summit Therapeutics Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was $0.00.
- Summit Therapeutics Inc. other nonoperating income (expense) for the quarter ending 2025-06-30 was -$53.00K.
- Summit Therapeutics Inc. other nonoperating income (expense) for fiscal 2025 was -$53.00K.
- Summit Therapeutics Inc. other nonoperating income (expense) for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. other nonoperating income (expense) for fiscal 2023 was -$252.00K, a 182.89% decline from fiscal 2022.
- Summit Therapeutics Inc. other nonoperating income (expense) for fiscal 2022 was $304.00K.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $500.00K 10-Q · filed 2026-07-23 | $500.00K 10-Q · filed 2026-07-23 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | -$53.00K derived: sum of 3 quarters · filed 2026-07-23 | -$53.00K 10-K · filed 2026-02-23 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-20 | -$53.00K derived: sum of 2 quarters · filed 2026-07-23 | -$53.00K 10-Q · filed 2025-10-20 | |
| 2025-06-30 | -$53.00K 10-Q · filed 2026-07-23 | -$53.00K 10-Q · filed 2026-07-23 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $0.00 derived: sum of 2 quarters · filed 2026-02-23 | $0.00 derived: sum of 3 quarters · filed 2026-02-23 | $0.00 10-K · filed 2026-02-23 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-20 | $0.00 derived: sum of 2 quarters · filed 2025-10-20 | $0.00 10-Q · filed 2025-10-20 | -$104.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | -$104.00K derived: sum of 3 quarters · filed 2026-02-23 | -$168.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-01 | -$104.00K derived: sum of 2 quarters · filed 2026-02-23 | -$168.00K derived: sum of 3 quarters · filed 2026-02-23 | -$173.00K derived: sum of 4 quarters · filed 2026-02-23 |
| 2023-12-31 | -$104.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$168.00K derived: sum of 2 quarters · filed 2026-02-23 | -$173.00K derived: sum of 3 quarters · filed 2026-02-23 | -$252.00K 10-K · filed 2026-02-23 |
| 2023-09-30 | -$64.00K 10-Q · filed 2024-10-30 | -$69.00K derived: sum of 2 quarters · filed 2024-10-30 | -$148.00K 10-Q · filed 2024-10-30 | $637.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-06-30 | -$5.00K 10-Q · filed 2024-08-06 | -$84.00K 10-Q · filed 2024-08-06 | $701.00K derived: sum of 3 quarters · filed 2025-02-24 | $747.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2023-03-31 | $417.00K 10-Q · filed 2024-05-01 | $706.00K derived: sum of 2 quarters · filed 2025-02-24 | $752.00K derived: sum of 3 quarters · filed 2025-02-24 | $738.00K derived: sum of 4 quarters · filed 2025-02-24 |
| 2022-12-31 | $289.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $335.00K derived: sum of 2 quarters · filed 2025-02-24 | $321.00K derived: sum of 3 quarters · filed 2025-02-24 | $304.00K 10-K · filed 2025-02-24 |
| 2022-09-30 | $46.00K 10-Q · filed 2023-11-07 | $32.00K derived: sum of 2 quarters · filed 2023-11-07 | $15.00K 10-Q · filed 2023-11-07 | $215.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$14.00K 10-Q · filed 2023-08-09 | -$31.00K 10-Q · filed 2023-08-09 | $169.00K derived: sum of 3 quarters · filed 2023-08-09 | $86.00K derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | -$17.00K 10-Q · filed 2023-05-11 | $183.00K derived: sum of 2 quarters · filed 2023-05-11 | $100.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | $117.00K derived: sum of 2 quarters · filed 2023-03-09 | -$39.00K 10-K · filed 2023-03-09 | |
| 2021-09-30 | -$83.00K 10-Q · filed 2022-11-09 | -$239.00K 10-Q · filed 2022-11-09 | ||
| 2020-09-30 | $416.00K 10-Q · filed 2020-11-16 | $296.00K 10-Q · filed 2020-11-16 | ||
| 2019-09-30 | -$75.00K 10-Q · filed 2020-11-16 | -$231.00K 10-Q · filed 2020-11-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |